Finance

Lists
TVRD:NASDAQ
Tvardi Therapeutics Inc
$0.81
+1.58%
(+0.012) 1D
$0.93
+15.48% (+0.12)
Pre-market
Closed: Nov 2, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TVRD...
Open
$0.83
High
$0.85
Low
$0.79
Mkt. cap
10.78M
Avg. vol.
201.70K
Volume
0.00
52-wk high
$5.69
52-wk low
$0.77
EPS
-$2.78
Beta
0.37
Shares outstanding
13.34M
No. of employees
12
Open
$0.83
High
$0.85
Low
$0.79
Mkt. cap
10.78M
Avg. vol.
201.70K
Volume
0.00
52-wk high
$5.69
52-wk low
$0.77
EPS
-$2.78
Beta
0.37
Shares outstanding
13.34M
No. of employees
12
News stories
From web sources and news partners
About Tvardi Therapeutics Inc
CEO-
Employees12
Founded2017
HeadquartersSugar Land, Texas, United States
SectorPharmaceutical industry
Websitetvarditherapeutics.com
Analyst ratings
Based on 7 analysts giving stock ratings to TVRD in the past 3 months
Buy
Buy
5
Hold
1
Sell
1
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for TVRD in the last 3 months.
Highest
Current $0.81
$14.00 (+1,638.48%)
Average
$8.17 (+914.53%)
Lowest
$3.00 (+272.53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gautam Chukka
Chardan Capital
Buy
Initiated
$8.00
+893.4%
10/20/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$10.00
+1,141.8%
09/15/2026
Elemer Piros
Lucid Capital
Buy
Initiated
$14.00
+1,638.5%
09/08/2026
Sara Nik
H.C. Wainwright
Buy
Maintained
$9.00
+1,017.6%
08/21/2026
Unknown Analyst
Cantor Fitzgerald
Hold
Maintained
-
-
08/19/2026
Julian Harrison
BTIG
Buy
Maintained
$5.00
+520.9%
08/19/2026
Etzer Darout
Barclays
Sell
Maintained
$3.00
+272.5%
08/20/2026
Yasmeen Rahimi
Piper Sandler
Buy
Upgraded
$13.00
+1,514.3%
07/08/2026
Ryan Deschner
Raymond James
Buy
Upgraded
$10.00
+1,141.8%
07/08/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$10.00
+1,141.8%
05/11/2026
Jay Olson
Oppenheimer
Buy
Maintained
$10.00
+1,141.8%
05/11/2026
Steven Seedhouse
Cantor Fitzgerald
Hold
Maintained
-
-
04/01/2026
Christopher Liu
Lucid Capital
Buy
Upgraded
$6.00
+645.1%
02/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
3.60M
5.49M
4.91M
4.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.34M
2.10M
2.14M
2.63M
Operating expense
5.94M
7.59M
7.05M
6.63M
Total operating expenses
5.94M
7.59M
7.05M
6.63M
Operating income
-5.94M
-7.59M
-7.05M
-6.63M
Other non operating income
-
-
-
-
EBT including unusual items
-5.53M
-7.28M
-6.80M
-6.46M
EBT excluding unusual items
-5.53M
-7.28M
-6.80M
-6.46M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-5.53M
-7.28M
-6.80M
-6.46M
Net profit margin
-
-
-
-
Earnings per share
-0.59
-0.78
-0.73
-0.69
Interest and investment income
411.00K
312.00K
247.00K
172.00K
Interest expense
-
-
-
-
Net interest expenses
411.00K
312.00K
247.00K
172.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-5.91M
-7.56M
-7.03M
-6.61M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps